Risk factors
Pulmonx (LUNG) risk factors
Item 1A of every Pulmonx Corp. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors86 risks8 new7 dropped17 reworded
Pulmonx added risks covering a new 40 million dollar credit agreement with Perceptive Credit Holdings.
Filed Mar 10, 2026 - FY2024 10-K risk factors85 risks
Pulmonx faces heavy reliance on its flagship Zephyr Valve and Chartis System for treating severe emphysema. The company has a history of significant net losses, totaling an accumulated deficit of $467.6 million as of December 31, 2024. Operations depend critically on single-source suppliers, a single headquarters manufacturing facility, and widespread physician and hospital adoption.
Filed Feb 25, 2025